|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
35,422 |
$2,131,341.74 |
7.20% |
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
17,843 |
$2,124,566.01 |
7.18% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
8,893 |
$2,082,562.74 |
7.03% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
9,520 |
$1,983,777.60 |
6.70% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
2,100 |
$1,946,763.00 |
6.58% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
39,951 |
$1,101,049.56 |
3.72% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
73,989 |
$1,086,158.52 |
3.67% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
1,413 |
$1,060,555.41 |
3.58% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
4,819 |
$1,031,217.81 |
3.48% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
8,426 |
$1,031,173.88 |
3.48% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
5,759 |
$1,021,358.65 |
3.45% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
7,416 |
$1,020,738.24 |
3.45% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
2,846 |
$1,011,183.80 |
3.42% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
2,223 |
$980,787.60 |
3.31% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
1,630 |
$959,059.40 |
3.24% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
3,347 |
$680,846.74 |
2.30% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
6,843 |
$669,382.26 |
2.26% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
3,657 |
$491,866.50 |
1.66% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
10,279 |
$461,424.31 |
1.56% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
865 |
$450,319.00 |
1.52% |
| PTC Therapeutics, Inc. |
PTCT |
69366J200 |
Biotechnology |
5,449 |
$394,671.07 |
1.33% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
2,127 |
$391,112.76 |
1.32% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
2,630 |
$350,447.50 |
1.18% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
6,318 |
$345,215.52 |
1.17% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
5,005 |
$346,796.45 |
1.17% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
8,380 |
$289,361.40 |
0.98% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
10,925 |
$258,704.00 |
0.87% |
| Spyre Therapeutics, Inc. |
SYRE |
00773J202 |
Biotechnology |
3,533 |
$257,944.33 |
0.87% |
| Travere Therapeutics, Inc. |
TVTX |
89422G107 |
Pharmaceuticals |
5,100 |
$207,927.00 |
0.70% |
| Twist Bioscience Corporation |
TWST |
90184D100 |
Biotechnology |
3,238 |
$193,664.78 |
0.65% |
| Amneal Pharmaceuticals, Inc. |
AMRX |
03168L105 |
Pharmaceuticals |
12,984 |
$180,607.44 |
0.61% |
| Arcus Biosciences, Inc. |
RCUS |
03969F109 |
Biotechnology |
7,459 |
$180,880.75 |
0.61% |
| Arrowhead Pharmaceuticals, Inc. |
ARWR |
04280A100 |
Biotechnology |
2,611 |
$181,490.61 |
0.61% |
| Ligand Pharmaceuticals Inc. (Class B) |
LGND |
53220K504 |
Biotechnology |
766 |
$177,574.12 |
0.60% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
5,049 |
$178,381.17 |
0.60% |
| Protagonist Therapeutics, Inc. |
PTGX |
74366E102 |
Biotechnology |
1,650 |
$174,867.00 |
0.59% |
| 10X Genomics, Inc. (Class A) |
TXG |
88025U109 |
Biotechnology |
6,591 |
$171,893.28 |
0.58% |
| Catalyst Pharmaceuticals, Inc. |
CPRX |
14888U101 |
Biotechnology |
6,583 |
$172,869.58 |
0.58% |
| Mirum Pharmaceuticals, Inc. |
MIRM |
604749101 |
Biotechnology |
1,646 |
$161,225.70 |
0.54% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
5,250 |
$156,607.50 |
0.53% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
551 |
$151,089.71 |
0.51% |
| Moderna, Inc. |
MRNA |
60770K107 |
Biotechnology |
2,836 |
$152,349.92 |
0.51% |
| Guardant Health, Inc. |
GH |
40131M109 |
Biotechnology |
1,618 |
$146,202.48 |
0.49% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
1,663 |
$145,861.73 |
0.49% |
| Alnylam Pharmaceuticals, Inc. |
ALNY |
02043Q107 |
Biotechnology |
456 |
$141,204.96 |
0.48% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
1,872 |
$141,729.12 |
0.48% |
| Supernus Pharmaceuticals, Inc. |
SUPN |
868459108 |
Pharmaceuticals |
2,776 |
$142,658.64 |
0.48% |
| Arcutis Biotherapeutics, Inc. |
ARQT |
03969K108 |
Biotechnology |
5,633 |
$138,177.49 |
0.47% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
6,186 |
$137,143.62 |
0.46% |
| Tarsus Pharmaceuticals, Inc. |
TARS |
87650L103 |
Biotechnology |
2,012 |
$135,286.88 |
0.46% |
| US Dollar |
$USD |
|
Other |
76,428 |
$76,428.44 |
0.26% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|